Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Pharmacological control of presbyopia: results of a pilot investigation

Search Title by author or title

Session Details

Session Title: Corneal, Scleral and Pharmaceutical Treatment of Presbyopia

Session Date/Time: Monday 09/10/2017 | 16:30-18:00

Paper Time: 17:46

Venue: Meeting Center Room I

First Author: : L.Vejarano COLOMBIA

Co Author(s): :    J. Alio                    

Abstract Details


To evaluate the predictability, reproducibility, efficacy, reliability and Safety of this innovative NON-invasive method for ameliorating Presbyopia.


Fundaci├│n Oftalmol├│gica Vejarano


Prospective study of results in real Accommodation and Dynamic Pseudo-Accommodation (subjective and objectively (with HD Analyzer, iTracey, OCT, UBM and Scheimpflug), defocus curve, refraction, visual acuity corrected and uncorrected for far and near distance, refractive change, pupil size and dynamism (Photopic and Scotopic), endothelial cell count, Schirmer test, IOP, Keratometry, Pachymetry, ACD and Anterior Chamber Volume using the FOV Tears, only one drop in each eye (not MONOVISION).


20 Presbyopic received FOV Tears; age average 49,65 yo, measurements were taken previously, 1/2, 1, 2, 3, 4 and 5 hours, 1 week and 1 month later. Globally results are: improving 1 line for Far and 3 for Near and 1-2 additional lines with continuous use, and gives extraordinary for Intermediate (20/25 or better), mild decrease of active Pupil Size, and No changes in Endothelial Cell count and lacrimal film, increase 0,75 Diopters in Accommodation Amplitude initially, increasing up to 1,80 D. with continued use, in Total gives 1,50 Diopters of Accommodation, improving with time of use until 2,50 Diopters.


This is a promising, NON-invasive and adjuvant solution for Presbyopia patients; generating enough independence of glasses for the most activities in the normal life of the patients with no risks neither secondary effects, incredible improve in intermediate vision, increasing the Accommodation Amplitude initially and more with continued use, also the Total Diopters of Accommodation.

Financial Disclosure:

has significant investment interest in a company producing, developing or supplying product or procedure presented

Back to previous